Search
Kiniksa Pharmaceuticals International PLC
KNSAAdd to Watchlist
76.275USD
-1.725-2.21%
Market hours 09/23, 11:44（ET）
5.95BMarket Cap
78.40P/E TTM
About Kiniksa Pharmaceuticals International PLC Company
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
Kiniksa Pharmaceuticals International PLC Profile
Ticker SymbolKNSA
Company nameKiniksa Pharmaceuticals International PLC
IPO dateMay 24, 2018
CEOPatel (Sanjiv K)
Number of employees315
Security typeOrdinary Share
Fiscal year-endMay 24
Address23 Old Bond Street, Floor 3
CityLONDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeWIS 4PZ
Phone
Websitehttps://www.kiniksa.com/
Ticker SymbolKNSA
IPO dateMay 24, 2018
CEOPatel (Sanjiv K)
Company Executives of Kiniksa Pharmaceuticals International PLC
Name
Name/Position
Position
Shareholding
Change
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
221.59K
--
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
221.59K
--
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
87.31K
+3.21%
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
87.31K
+3.21%
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
69.92K
+6.15%
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
69.92K
+6.15%
Mr. Eben Tessari
Mr. Eben Tessari
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
66.21K
+74.28%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
22.36K
+1.80%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
22.36K
+1.80%
Mr. Mark Ragosa
Mr. Mark Ragosa
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
20.85K
+22.54%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
221.59K
--
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
221.59K
--
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
87.31K
+3.21%
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
87.31K
+3.21%
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
69.92K
+6.15%
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
69.92K
+6.15%
FAQs
Who are the top five shareholders of Kiniksa Pharmaceuticals International PLC?
The top five shareholders of Kiniksa Pharmaceuticals International PLC are: Mr. Sanjiv K. (Sanj) Patel
How many institutions hold shares of Kiniksa Pharmaceuticals International PLC (KNSA)?
As of 2026Q1, 483 institutions hold shares of Kiniksa Pharmaceuticals International PLC, with a combined market value of approximately 51.67M, accounting for 111.58% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 2211552.00.